Drug Deliv. and Transl. Res.
Funding information This work was financially supported by the
National Basic Research Program of China (973 Program, No.
13. Mayr J, Heffeter P, Groza D, Galvez L, Koellensperger G, Roller A,
et al. An albumin-based tumor-targeted oxaliplatin prodrug with
distinctly improved anticancer activity in vivo. Chem Sci.
2017;8(3):2241–50.
2
015CB932100) and the innovation team project of education depart-
ment of Liaoning province (LT 2014022).
1
4. Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression
correlates with tumor response to albumin-bound paclitaxel in head
and neck cancer patients. Transl Oncol. 2009;2:59–64.
Compliance with ethical standards
1
5. Lin T, Zhao P, Jiang Y, Tang Y, Jin H, Pan Z, et al. Blood-brain-
barrier-penetrating albumin nanoparticles for biomimetic drug de-
livery via albumin-binding protein pathways for antiglioma therapy.
ACS Nano. 2016;10(11):9999–10012.
Conflict of interest The authors declare that they have no conflicts of
interest.
1
6. Chung SW, Choi JU, Lee BS, Byun J, Jeon OC, Kim SW, et al.
Albumin-binding caspase-cleavable prodrug that is selectively acti-
vated in radiation exposed local tumor. Biomaterials. 2016;94:1–8.
7. Zhao D, Zhang H, Tao W, Wei W, Sun J, He Z. A rapid albumin-
binding 5-fluorouracil prodrug with a prolonged circulation time
and enhanced antitumor activity. Biomater Sci. 2017;5(3):502–10.
References
1
1
2
3
4
.
.
.
.
Sun YB, Shi SL, Jing YK, Yin SL, Chen GL, Xu YJ, et al.
Synthesis, transport and pharmacokinetics of 5′-amino acid ester
prodrugs of 1-D-arabinofuranosylcytosine. Mol Pharm. 2008;6:
18. Abu Ajaj K, Graeser R, Fichtner I, Kratz F. In vitro and in vivo
study of an albumin-binding prodrug of doxorubicin that is cleaved
by cathepsin B. Cancer Chemother Pharmacol. 2009;64(2):413–8.
19. Abu Ajaj K, Graeser R, Kratz F. Zosuquidar and an albumin-
binding prodrug of zosuquidar reverse multidrug resistance in
breast cancer cells of doxorubicin and an albumin-binding prodrug
of doxorubicin. Breast Cancer Res Treat. 2012;134(1):117–29.
3
15–25.
Liu YG, Dai QL, Wang SB, Deng QJ, Wu WG, Chen AZ.
Preparation and in vitro antitumor effects of cytosine arabinoside-
loaded genipin-poly-l-glutamic acid-modified bacterial
magnetosomes. Int J Nanomedicine. 2015;10:1387–97.
Webster JA, Tibes R, Morris L, Blackford AL, Litzow M, Patnaik
M, et al. Randomized phase II trial of cytosine arabinoside with and
without the CHK1 inhibitor MK-8776 in relapsed and refractory
acute myeloid leukemia. Leuk Res. 2017;61:108–16.
DeAngelis LM, Kreis W, Chan K, Dantis E, Akerman S.
Pharmacokinetics of ara-C and ara-U in plasma and CSF after
high-dose administration of cytosine arabinoside. Cancer
Chemother Pharmacol. 1992;29(3):173–7.
Hamada A, Kawaguchi T, Nakano M. Clinical pharmacokinetics of
cytarabine formulations. Clin Pharmacokinet. 2002;41(10):705–18.
Bhushan B, Khanadeev V, Khlebtsov B, Khlebtsov N, Gopinath P.
Impact of albumin based approaches in nanomedicine: imaging,
targeting and drug delivery. Adv Colloid Interf Sci. 2017;246:13–39.
Kratz F. Albumin as a drug carrier: design of prodrugs, drug con-
jugates and nanoparticles. J Control Release. 2008;132(3):171–83.
Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for
drug half-life extension. Biochim Biophys Acta. 2013;1830(12):
2
0. Elsadek B, Graeser R, Esser N, Schafer-Obodozie C, Tsurumi C,
Abu Ajaj K, et al. In vivo evaluation of a novel albumin-binding
prodrug of doxorubicin in an orthotopic mouse model of prostate
cancer (LNCaP). Prostate Cancer Prostatic Dis. 2011;14(1):14–21.
1. Kratz F. DOXO-EMCH (INNO-206): the first albumin-binding
prodrug of doxorubicin to enter clinical trials. Expert Opin
Investig Drugs. 2007;16(6):855–66.
2
2
2. Wang G, Chen H, Zhao D, Ding D, Sun M, Kou L, et al.
Combination of l-carnitine with lipophilic linkage-donating
gemcitabine derivatives as intestinal novel organic cation transport-
er 2-targeting oral prodrugs. J Med Chem. 2017;60(6):2552–61.
3. Chen H, Wang G, Sun L, Zhang H, Sun M, Sun J et al. Regulating
the alky chain length of fatty acid-didanosine prodrugs and evalu-
ating its role in albumin binding. Drug Deliv Transl Res 2017
4. Absar S, Nahar K, Choi S, Ahsan F, Yang VC, Kwon YM. Serum
albumin-protamine conjugate for biocompatible platform for
targeted delivery of therapeutic macromolecules. J Biomed Mater
Res A. 2014;102(8):2481–90.
5
.
.
6
2
2
7
.
.
8
5
526–34.
9
.
Miele E, Spinelli GP, Tomao F, Tomao S. Albumin-bound formu-
lation of paclitaxel (Abraxane ABI-007) in the treatment of breast
cancer. Int J Nanomedicine. 2009;4:99–105.
2
2
2
5. Mehtala JG, Kulczar C, Lavan M, Knipp G, Wei A. Cys34-
PEGylated human serum albumin for drug binding and delivery.
Bioconjug Chem. 2015;26(5):941–9.
6. Hu X, Song W, Li W, Guo C, Yu Z, Liu R. Effects of gamma-
irradiation on the molecular structures and functions of human se-
rum albumin. J Biochem Mol Toxicol. 2016;30(11):525–32.
7. Tian ZY, Song LN, Zhao Y, Zang FL, Zhao ZH, Chen NH, et al.
Spectroscopic study on the interaction between naphthalimide-
polyamine conjugates and bovine serum albumin (BSA).
Molecules. 2015;20(9):16491–523.
1
0. Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM,
Bhar P, et al. Abraxane, a novel Cremophor-free, albumin-bound
particle form of paclitaxel for the treatment of advanced non-small-
cell lung cancer. Ann Oncol. 2006;17:1263–8.
1
1. Maeda H. Vascular permeability in cancer and infection as related to
macromolecular drug delivery, with emphasis on the EPR effect for
tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci.
2
012;88:53–71.
28. Tao W, Zhao D, Sun M, Li M, Zhang X, He Z, et al. Enzymatic
activation of double-targeted 5'-O-L-valyl-decitabine prodrug by
biphenyl hydrolase-like protein and its molecular design basis.
Drug Deliv Transl Res. 2017;7(2):304–11.
1
2. Maeda H. Toward a full understanding of the EPR effect in primary
and metastatic tumors as well as issues related to its heterogeneity.
Adv Drug Deliv Rev. 2015;91:3–6.